20 completed, 6 terminated, 4 active not recruiting, 4 recruiting. 25 Phase 2, 18 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 25 | Completed 14, Active not recruiting 4, Recruiting 3, Terminated 2, Withdrawn 2 |
| Phase 1 | 18 | Completed 11, Terminated 4, Recruiting 1, Unknown 1, Withdrawn 1 |
Follow Recurrent Hodgkin Lymphoma: new trials by email Literature Review of Recurrent Hodgkin Lymphoma trials Research Report on Recurrent Hodgkin Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma Biospecimen Collection, Computed Tomography, Decitabine and Cedazuridine - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 32 | 2022-11-03 | 2026-09-10 |
| Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma Basiliximab, Carmustine, Cytarabine - Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 33 | 2021-11-02 | 2025-12-04 |
| Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Anti-Thymocyte Globulin, Busulfan, Cyclophosphamide - Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Withdrawn | Fred Hutchinson Cancer Center | 2021-06-01 | 2021-06-30 | |
| Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple Myeloma Choline Salicylate, Selinexor - Recurrent Histiocytic and Dendritic Cell Neoplasm, Recurrent Hodgkin Lymphoma | Phase 1 | Completed | Mayo Clinic | 22 | 2021-02-08 | 2026-05-28 |
| Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies Acetaminophen, Dexamethasone, Diphenhydramine - Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 | Completed | City of Hope Medical Center | 13 | 2020-11-18 | 2026-01-28 |
| Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer Anti-CD123/CD3 Monoclonal Antibody MGD006 - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Withdrawn | City of Hope Medical Center | 2020-10-20 | 2020-12-17 | |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
| Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Bendamustine, Gemcitabine, Nivolumab - Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | Emory University | 3 | 2018-11-26 | 2025-08-06 |
| Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer Belinostat, Carfilzomib, Copanlisib Hydrochloride - Breast Adenocarcinoma, Metastatic Breast Carcinoma | Phase 1 | Terminated | Mayo Clinic | 17 | 2018-03-27 | 2025-05-26 |
| Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia Ascorbic Acid, Carboplatin, Cisplatin - Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | Phase 2 | Recruiting | Mayo Clinic | 80 | 2018-03-23 | 2026-09-28 |
| Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) Tazemetostat - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 20 | 2017-11-13 | 2026-04-13 |
| Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma Anti-Thymocyte Globulin, Busulfan, Clofarabine - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 6 | 2017-10-13 | 2023-10-11 |
| Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 150 | 2017-09-11 | 2026-05-14 |
| Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL Carboplatin, Etoposide, Ifosfamide - Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma | Phase 2 | Active not recruiting | City of Hope Medical Center | 78 | 2017-05-08 | 2026-11-02 |
| Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma Brentuximab Vedotin, Laboratory Biomarker Analysis, Nivolumab - Classic Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma | Phase 2 | Active not recruiting | City of Hope Medical Center | 62 | 2017-05-03 | 2026-10-26 |
| Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma Brentuximab Vedotin, Cyclosporine, Pharmacokinetic Study - Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma | Phase 1 | Completed | City of Hope Medical Center | 29 | 2017-05-03 | 2024-02-22 |
| Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Cyclophosphamide, Filgrastim, Fludarabine Phosphate - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 1 | Completed | M.D. Anderson Cancer Center | 11 | 2017-01-18 | 2023-02-16 |
| Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant Ibrutinib, Laboratory Biomarker Analysis - Blastoid Variant Mantle Cell Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 2 | Completed | Vanderbilt-Ingram Cancer Center | 23 | 2016-11-01 | 2023-10-23 |
| Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Cyclophosphamide - Hematopoietic and Lymphoid Cell Neoplasm, High Risk Acute Myeloid Leukemia | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 204 | 2016-08-05 | 2026-08-06 |
| Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma Brentuximab Vedotin, Ibrutinib - Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma | Phase 2 | Completed | City of Hope Medical Center | 39 | 2016-07-01 | 2026-11-06 |
Showing 20 of 38. Sign in to see all of them.
Hodgkin Disease (38) · Lymphoma, Non-Hodgkin (18) · Leukemia, Myeloid, Acute (13) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (13) · Multiple Myeloma (11) · Myelodysplastic Syndromes (11) · Leukemia, Lymphocytic, Chronic, B-Cell (10) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (9) · Lymphoma, Mantle-Cell (7) · Hematologic Neoplasms (6) · Leukemia, Myeloid, Chronic-Phase (6) · Leukemia, Myelomonocytic, Chronic (6) · Lymphoma, Large B-Cell, Diffuse (6) · Leukemia, Biphenotypic, Acute (5) · Myelodysplastic-Myeloproliferative Diseases (5)
Hemic and Lymphatic Diseases (38) · Immune System Diseases (38) · Immunoproliferative Disorders (38) · Lymphatic Diseases (38) · Neoplasms (38) · Neoplasms by Histologic Type (38) · Lymphoproliferative Disorders (37) · Lymphoma (36) · Hematologic Diseases (18) · Bone Marrow Diseases (17) · Chronic Disease (17) · Disease Attributes (17) · Leukemia (17) · Pathologic Processes (17) · Pathological Conditions, Signs and Symptoms (17)
Nivolumab (9) · Cyclophosphamide (8) · Mycophenolic Acid (8) · Whole-Body Irradiation (8) · fludarabine phosphate (8) · Brentuximab Vedotin (7) · CT-P10 (6) · Peripheral Blood Stem Cell Transplantation (6) · Rituximab (6) · Tacrolimus (6) · Cyclosporine (5) · Cyclosporins (5) · Etoposide (5) · Melphalan (5) · Busulfan (4)
Fred Hutchinson Cancer Center (9) · City of Hope Medical Center (8) · M.D. Anderson Cancer Center (5) · National Cancer Institute (NCI) (5) · Mayo Clinic (4) · University of Washington (2) · Barbara Ann Karmanos Cancer Institute (1) · Emory University (1) · OHSU Knight Cancer Institute (1) · Vanderbilt-Ingram Cancer Center (1) · Virginia Commonwealth University (1)
United States (37) · Canada (1) · Denmark (1) · Germany (1) · Italy (1) · Puerto Rico (1)
Ajay Gopal (3) · Alex F Herrera (3) · Alex Herrera (2) · Brenda Sandmaier (2) · Masumi Ueda Oshima (2) · Ajay K. Gopal (1) · Amanda Olson (1) · Amir A Toor, MD (1) · Bhagirathbhai Dholaria, M.D. (1) · Catherine S Diefenbach (1) · Chitra Hosing (1) · Crystal L Mackall (1) · Dipenkumar Modi, M.D. (1) · Grzegorz S. Nowakowski, M.D. (1) · Hans-Peter Kiem (1)
PMID 26211987, PMID 27410923, PMID 29272364, PMID 31401903, PMID 31508518, PMID 32192573, PMID 32478814, PMID 32499241, PMID 32603426, PMID 33720354, PMID 34329577, PMID 35316328, PMID 35622074, PMID 36403579, PMID 37611156, PMID 39352751, PMID 39863139, PMID 41043099
P30CA015704 (8), P30CA033572 (3), P01CA018029 (2), P01CA044991 (2), P01CA078902 (2), P30CA016672 (2), P50CA097274 (2), P01CA229086 (1), P30CA006516 (1), P30CA015083 (1), P30CA016087 (1), P30CA022453 (1), P30CA138292 (1), P50CA107399 (1), R01CA183559 (1)